Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 13/20 | 0.54 |
| ▸ | CDK4 | P11802 | 11/20 | 0.54 |
| ▸ | CCND1 | P24385 | 11/20 | 0.54 |
| ▸ | CDK9 | P50750 | 9/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.54 |
| ▸ | CDK2 | P24941 | 4/20 | 0.54 |
| ▸ | CDK1 | P06493 | 3/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 3/20 | 0.43 |
| ▸ | CDK8 | P49336 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CCNH | P51946 | 2/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24304984 | 0.87 | CDK4 (0.55) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL18081420 | 0.86 | CDK4 (0.54) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL17469717 | 0.86 | CDK4 (0.54) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL21345115 | 0.84 | CDK6 (0.61) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL22650377 | 0.82 | CDK6 (0.38) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL21345192 | 0.81 | CDK6 (0.61) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL18081413 | 0.81 | CDK6 (0.40) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL18081385 | 0.80 | CDK4 (0.44) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL20740537 | 0.78 | JAK2 (0.38) | CDK6CDK4CCND1CDK9CCNT1 | |
| SCHEMBL20356534 | 0.78 | CDK6 (0.37) | CDK6CDK4CCND1CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595246-B2 | Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| CN-111333627-B | Substituted 2-hydro-pyrazole derivatives as anticancer agents | 正大天晴药业集团股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-3941472-B1 | CRYSTALLINE AND AMORPHOUS FORMS OF-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL)PYRIDINE-2-YL)-5-FLUORO-4-(3-ISOPROPYL-2-METHYL-2 <NS1:I>H</NS1:I>?-INDAZOL-5-YL)PYRIMIDIN-2-AMINE AND ITS SALTS, AND PREPARATION METHODS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-113840605-B | Crystalline forms of N- (5- ((4-ethylpiperazin-1-yl) methyl) pyridin-2-yl) -5-fluoro-4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-amine hydrochloride and uses thereof | 贝达医药公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230331699-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-3746072-B1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3746072-B1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11352341-B2 | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352341-B2 | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220162185-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL)PYRIDINE-2-YL)-5-FLUORO-4-(3-ISOPROPYL-2-METHYL-2H-INDAZOL-5-YL)PYRIMIDIN-2-AMINE AND ITS SALTS, AND PREPARATION METHODS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. | 2022-05-26 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3191469-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016141881-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | 南京明德新药研发股份有限公司 | 2016-09-15 | — | — | WO | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352341-B2 | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | CDK4, CDK6, CDK3 | CDK6 2/4885CDK4 1/4885CCND1 24/4885 |
| US-20220162185-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL)PYRIDINE-2-YL)-5-FLUORO-4-(3-ISOPROPYL-2-METHYL-2H-INDAZOL-5-YL)PYRIMIDIN-2-AMINE AND ITS SALTS, AND PREPARATION METHODS AND THERAPEUTIC USES THEREOF | CDK6, CDK4, CDK2 | CDK6 1/4885CDK4 2/4885CCND1 49/4885 |
| US-20230331699-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CDK4, CDK6, CDK2 | CDK6 2/4885CDK4 1/4885CCND1 36/4885 |
| US-12595246-B2 | Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof | CDK6, CDK4, CDK2 | CDK6 1/4885CDK4 2/4885CCND1 27/4885 |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | CDK4, CDK3, CDK6 | CDK6 3/4885CDK4 1/4885CCND1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.